Roger McIntyre, MD, FRCPC, and Joseph Goldberg, MD, discuss mood disorders, antipsychotics and tardive dyskinesia (TD).
Leslie Citrome, MD, MPH, and Joseph P. McEvoy, MD, discuss diagnosis of tardive dyskinesia (TD) in clinical practice.
John M. Kane, MD, and Rebecca S. Roma, MD, discuss the relationship of extrapyramidal symptoms, antiparkinsonian drugs, and tardive dyskinesia.
In this episode, Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh , discuss how the use of antipsychotics has changed in primary care patients, how primary care physicians can screen for tardive dyskinesia (TD), and increasing needs for the primary care physician in mental health.
Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh, discuss a multidisciplinary approach to the evaluation and treatment of patients with tardive dyskinesia.
Diana Perkins, MD, MPH, and Martha Sajatovic, MD, discuss the functional and social impact of tardive dyskinesia on the lives of patients.
The use of telemedicine to aid in the assessment of patients with tardive dyskinesia has emerged. Here are my key insights on how it could be used.
Early recognition of signs and symptoms potentially associated with TD can lead to improved understanding of the diagnosis, consideration of treatment options, and better long-term patient outcomes. Here are my key insights on TD identification.
Anticholinergics improve parkinsonism but exacerbate TD, and VMAT2 inhibitors improve TD but do not treat parkinsonism and may worsen it. Jonathan Meyer, MD, explores this psychopharmacology topic and reflects on processes acting on different neurons.
Tardive dyskinesia (TD) has a real-world impact on patient lives. Greg Mattingly, MD, explores the social and emotional impact of TD on patients as well as its prevalence and diagnosis.
The availability of 2 FDA-approved agents for the treatment of tardive dyskinesia has been a tremendous accomplishment. In this ClinicalThought, I explore the choices of FDA-approved agents to treat tardive dyskinesia and review what to consider.
The burden of schizophrenia and tardive dyskinesia is extensive. In this expert commentary, Martha Sajatovic, MD, explores the American Psychiatric Association 2021 practice guidelines on tardive dyskinesia management in schizophrenia and the advancements in pharmacologic and psychosocial treatments.
Formulate an approach to select the right treatment for patients with tardive dyskinesia.
Formulate an approach to diagnose patients with tardive dyskinesia.
This eCase explores diagnosis and treatment of tardive dyskinesia in an older female patient with a history of bipolar disorder.
This eCase explores diagnosis and treatment of tardive dyskinesia in a male patient with schizophrenia.
This eCase explores the diagnosis and treatment of tardive dyskinesia in a female patient with a long history of bipolar disorder.
This eCase explores diagnosis, treatment, and impact of tardive dyskinesia in patients with mood disorders.
In the journal supplement to Current Psychiatry, diagnostic dilemmas and choosing the right treatment in patients with tardive dyskinesia (TD) were covered by Manish Jha, MBBS and Greg Mattingly, MD. These articles covered an overview of TD, identification of traditional treatment approaches to TD and their limitations, and details from recent research relating to the efficacy and safety of novel treatment options for TD.
To complete the evaluation and claim credit, please click “Begin Activity” at left and then “Claim Credit” on the next screen.
Two expert faculty members discuss key articles in tardive dyskinesia research and the clinical implications, strengths, limitations, and salient conclusions.
In this interactive recording of a live CCO webinar, Greg Mattingly, MD, and Manish Jha, MBBS, discuss diagnostic dilemmas with tardive dyskinesia, as well as choosing the right treatment.